Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports.
According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “
Separately, Maxim Group reaffirmed a buy rating and issued a $315.00 price objective (up from $305.00) on shares of Domino’s Pizza in a research note on Wednesday, April 24th.
Shares of Pluristem Therapeutics stock remained flat at $$0.55 during trading hours on Wednesday. 404,590 shares of the company’s stock were exchanged, compared to its average volume of 430,694. Pluristem Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.38. The firm has a market cap of $79.48 million, a PE ratio of -2.19 and a beta of 0.92. The stock has a 50 day simple moving average of $0.60.
Pluristem Therapeutics (NASDAQ:PSTI) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, research analysts forecast that Pluristem Therapeutics will post -0.31 EPS for the current year.
Several hedge funds have recently made changes to their positions in PSTI. Van ECK Associates Corp raised its holdings in shares of Pluristem Therapeutics by 38.7% in the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 14,087 shares during the last quarter. Virtu Financial LLC raised its holdings in shares of Pluristem Therapeutics by 266.1% in the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 61,858 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Pluristem Therapeutics in the first quarter valued at about $881,000. Nikko Asset Management Americas Inc. purchased a new stake in shares of Pluristem Therapeutics in the first quarter valued at about $900,000. Finally, ARK Investment Management LLC raised its holdings in shares of Pluristem Therapeutics by 12.0% in the first quarter. ARK Investment Management LLC now owns 3,793,249 shares of the biotechnology company’s stock valued at $3,679,000 after purchasing an additional 406,155 shares during the last quarter. Institutional investors own 6.00% of the company’s stock.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Article: Limitations of the P/E Growth ratio
Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.